TY  - JOUR
AU  - Stojić-Vukanić, Zorica
AU  - Čolić, Miodrag
AU  - Backović, A.
AU  - Antić-Stanković, Jelena
AU  - Bufan, Biljana
AU  - Dimitrijević, M.
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1580
AB  - Leflunomide is an immunosuppressive drug effective in experimental models of transplantation and autoimmune diseases and in the treatment of active rheumatoid arthritis (RA). Having in mind that it has been shown that some other immunosuppressive drugs (glucocorticoids, mycophenolate mofetil, sirolimus etc.) impair dendritic cell (DC) phenotype and function, we investigated the effect of A77 1726, an active metabolite of leflunomide, on the differentiation and function of human monocyte-derived dendritic cells (MDDC) in vitro. Immature MDDC were generated by cultivating monocytes in medium supplemented with GM-CSF and IL-4. To induce maturation, immature MDDC were cultured for 2 additional days with LPS. A77 1726 (100 μM) was added at the beginning of cultivation. Flow cytometric analysis showed that MDDC differentiated in the presence of A77 1726 exhibited an altered phenotype, with a down-regulated surface expression of CD80, CD86, CD54 and CD40 molecules. Furthermore, the continuous presence of A77 1726 during differentiation and maturation prevented successful maturation, judging by the decreased expression of maturation marker CD83, costimulatory and adhesive molecules on A77 1726-treated mature MDDC. In addition, A77 1726-pretreated MDDC exhibited a poor stimulatory capacity of the allogeneic T cells and a low production of IL-10 and IL-18. These data suggest that leflunomide impairs the differentiation, maturation and function of human MDDC in vitro, which is an additional mechanism of its immunosuppressive effect.
PB  - Srpsko biološko društvo, Beograd, i dr.
T2  - Archives of Biological Sciences
T1  - Differentiation and function of human monocyte-derived dendritic cells under the influence of leflunomide
VL  - 63
IS  - 2
SP  - 353
EP  - 364
DO  - 10.2298/ABS1102353S
ER  - 

@article{
author = "Stojić-Vukanić, Zorica and Čolić, Miodrag and Backović, A. and Antić-Stanković, Jelena and Bufan, Biljana and Dimitrijević, M.",
year = "2011",
abstract = "Leflunomide is an immunosuppressive drug effective in experimental models of transplantation and autoimmune diseases and in the treatment of active rheumatoid arthritis (RA). Having in mind that it has been shown that some other immunosuppressive drugs (glucocorticoids, mycophenolate mofetil, sirolimus etc.) impair dendritic cell (DC) phenotype and function, we investigated the effect of A77 1726, an active metabolite of leflunomide, on the differentiation and function of human monocyte-derived dendritic cells (MDDC) in vitro. Immature MDDC were generated by cultivating monocytes in medium supplemented with GM-CSF and IL-4. To induce maturation, immature MDDC were cultured for 2 additional days with LPS. A77 1726 (100 μM) was added at the beginning of cultivation. Flow cytometric analysis showed that MDDC differentiated in the presence of A77 1726 exhibited an altered phenotype, with a down-regulated surface expression of CD80, CD86, CD54 and CD40 molecules. Furthermore, the continuous presence of A77 1726 during differentiation and maturation prevented successful maturation, judging by the decreased expression of maturation marker CD83, costimulatory and adhesive molecules on A77 1726-treated mature MDDC. In addition, A77 1726-pretreated MDDC exhibited a poor stimulatory capacity of the allogeneic T cells and a low production of IL-10 and IL-18. These data suggest that leflunomide impairs the differentiation, maturation and function of human MDDC in vitro, which is an additional mechanism of its immunosuppressive effect.",
publisher = "Srpsko biološko društvo, Beograd, i dr.",
journal = "Archives of Biological Sciences",
title = "Differentiation and function of human monocyte-derived dendritic cells under the influence of leflunomide",
volume = "63",
number = "2",
pages = "353-364",
doi = "10.2298/ABS1102353S"
}

Stojić-Vukanić, Z., Čolić, M., Backović, A., Antić-Stanković, J., Bufan, B.,& Dimitrijević, M.. (2011). Differentiation and function of human monocyte-derived dendritic cells under the influence of leflunomide. in Archives of Biological Sciences
Srpsko biološko društvo, Beograd, i dr.., 63(2), 353-364.
https://doi.org/10.2298/ABS1102353S

Stojić-Vukanić Z, Čolić M, Backović A, Antić-Stanković J, Bufan B, Dimitrijević M. Differentiation and function of human monocyte-derived dendritic cells under the influence of leflunomide. in Archives of Biological Sciences. 2011;63(2):353-364.
doi:10.2298/ABS1102353S .

Stojić-Vukanić, Zorica, Čolić, Miodrag, Backović, A., Antić-Stanković, Jelena, Bufan, Biljana, Dimitrijević, M., "Differentiation and function of human monocyte-derived dendritic cells under the influence of leflunomide" in Archives of Biological Sciences, 63, no. 2 (2011):353-364,
https://doi.org/10.2298/ABS1102353S . .

TY  - JOUR
AU  - Stojić-Vukanić, Zorica
AU  - Čolić, Miodrag
AU  - Dimitrijević, M.
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/917
AB  - Pentoxifylline (PTX) is a drug used for the treatment of vascular disorders, but it also has a positive therapeutic effect in experimental models of some autoimmune diseases. In this work, we studied the effect of PTX on human monocyte-derived dendritic cells (MDDCs). Immature MDDCs were generated in vitro from monocytes in the presence of recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and recombinant human interleukin-4 (rhIL-4), while mature MDDCs were obtained by cultivation of immature MDDCs with lipopolysaccharide (LPS). PTX (200 mu g/ml) was added at the beginning of cell cultivation. We found that PTX significantly impaired differentiation and function of immature NIDDCs, as judged by the reduced allostimulatory activity of these cells on allogeneic T cells and down-regulation of costimulatory and adhesion molecules, such as CD86, CD40 and CD54. The maturation of MDDCs in the presence of PTX and LPS was characterized by the decreased expression of maturation marker CD83 and costimulatory molecule CD86, as well as lower stimulation of alloreactive T cells compared to the control MDDCs cultivated with LPS alone. PTX-treated MDDCs which were induced to mature with LPS produced lower levels of TNF-alpha, IL-12 and IL-18 and higher levels of IL-10 than corresponding control NIDDCs. PTX did not significantly alter endocytosis of dextran by both immature and mature MDDCs. Cumulatively, our results show for the first time that PTX might impair differentiation, maturation and function of human MDDCs in vitro, suggesting an additional mechanism of its immunomodulatory activity.
PB  - Elsevier Science BV, Amsterdam
T2  - International Immunopharmacology
T1  - Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro
VL  - 7
IS  - 2
SP  - 167
EP  - 174
DO  - 10.1016/j.intimp.2006.09.005
ER  - 

@article{
author = "Stojić-Vukanić, Zorica and Čolić, Miodrag and Dimitrijević, M.",
year = "2007",
abstract = "Pentoxifylline (PTX) is a drug used for the treatment of vascular disorders, but it also has a positive therapeutic effect in experimental models of some autoimmune diseases. In this work, we studied the effect of PTX on human monocyte-derived dendritic cells (MDDCs). Immature MDDCs were generated in vitro from monocytes in the presence of recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and recombinant human interleukin-4 (rhIL-4), while mature MDDCs were obtained by cultivation of immature MDDCs with lipopolysaccharide (LPS). PTX (200 mu g/ml) was added at the beginning of cell cultivation. We found that PTX significantly impaired differentiation and function of immature NIDDCs, as judged by the reduced allostimulatory activity of these cells on allogeneic T cells and down-regulation of costimulatory and adhesion molecules, such as CD86, CD40 and CD54. The maturation of MDDCs in the presence of PTX and LPS was characterized by the decreased expression of maturation marker CD83 and costimulatory molecule CD86, as well as lower stimulation of alloreactive T cells compared to the control MDDCs cultivated with LPS alone. PTX-treated MDDCs which were induced to mature with LPS produced lower levels of TNF-alpha, IL-12 and IL-18 and higher levels of IL-10 than corresponding control NIDDCs. PTX did not significantly alter endocytosis of dextran by both immature and mature MDDCs. Cumulatively, our results show for the first time that PTX might impair differentiation, maturation and function of human MDDCs in vitro, suggesting an additional mechanism of its immunomodulatory activity.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "International Immunopharmacology",
title = "Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro",
volume = "7",
number = "2",
pages = "167-174",
doi = "10.1016/j.intimp.2006.09.005"
}

Stojić-Vukanić, Z., Čolić, M.,& Dimitrijević, M.. (2007). Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. in International Immunopharmacology
Elsevier Science BV, Amsterdam., 7(2), 167-174.
https://doi.org/10.1016/j.intimp.2006.09.005

Stojić-Vukanić Z, Čolić M, Dimitrijević M. Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. in International Immunopharmacology. 2007;7(2):167-174.
doi:10.1016/j.intimp.2006.09.005 .

Stojić-Vukanić, Zorica, Čolić, Miodrag, Dimitrijević, M., "Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro" in International Immunopharmacology, 7, no. 2 (2007):167-174,
https://doi.org/10.1016/j.intimp.2006.09.005 . .

TY  - CONF
AU  - Stojić-Vukanić, Zorica
AU  - Čolić, Miodrag
AU  - Backović, A.
AU  - Antić-Stanković, Jelena
AU  - Dimitrijević, M.
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/684
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro
T1  - In vitro efekat pentoksifilina na diferencijaciju i maturaciju humanih dendritičnih ćelija monocitnog porekla
VL  - 56
IS  - 4
SP  - 410
EP  - 411
UR  - https://hdl.handle.net/21.15107/rcub_farfar_684
ER  - 

@conference{
author = "Stojić-Vukanić, Zorica and Čolić, Miodrag and Backović, A. and Antić-Stanković, Jelena and Dimitrijević, M.",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro, In vitro efekat pentoksifilina na diferencijaciju i maturaciju humanih dendritičnih ćelija monocitnog porekla",
volume = "56",
number = "4",
pages = "410-411",
url = "https://hdl.handle.net/21.15107/rcub_farfar_684"
}

Stojić-Vukanić, Z., Čolić, M., Backović, A., Antić-Stanković, J.,& Dimitrijević, M.. (2006). Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(4), 410-411.
https://hdl.handle.net/21.15107/rcub_farfar_684

Stojić-Vukanić Z, Čolić M, Backović A, Antić-Stanković J, Dimitrijević M. Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. in Arhiv za farmaciju. 2006;56(4):410-411.
https://hdl.handle.net/21.15107/rcub_farfar_684 .

Stojić-Vukanić, Zorica, Čolić, Miodrag, Backović, A., Antić-Stanković, Jelena, Dimitrijević, M., "Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro" in Arhiv za farmaciju, 56, no. 4 (2006):410-411,
https://hdl.handle.net/21.15107/rcub_farfar_684 .

TY  - JOUR
AU  - Stojić-Vukanić, Zorica
AU  - Dimitrijević, M
AU  - Colić, M
AU  - Popović, P
AU  - Jandrić, Dušan
PY  - 2001
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/287
PB  - Elsevier Science Inc, New York
T2  - Turkish Journal of Medical Sciences
T1  - Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline
VL  - 33
IS  - 3
SP  - 2137
EP  - 2138
DO  - 10.1016/S0041-1345(01)01975-3
ER  - 

@article{
author = "Stojić-Vukanić, Zorica and Dimitrijević, M and Colić, M and Popović, P and Jandrić, Dušan",
year = "2001",
publisher = "Elsevier Science Inc, New York",
journal = "Turkish Journal of Medical Sciences",
title = "Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline",
volume = "33",
number = "3",
pages = "2137-2138",
doi = "10.1016/S0041-1345(01)01975-3"
}

Stojić-Vukanić, Z., Dimitrijević, M., Colić, M., Popović, P.,& Jandrić, D.. (2001). Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline. in Turkish Journal of Medical Sciences
Elsevier Science Inc, New York., 33(3), 2137-2138.
https://doi.org/10.1016/S0041-1345(01)01975-3

Stojić-Vukanić Z, Dimitrijević M, Colić M, Popović P, Jandrić D. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline. in Turkish Journal of Medical Sciences. 2001;33(3):2137-2138.
doi:10.1016/S0041-1345(01)01975-3 .

Stojić-Vukanić, Zorica, Dimitrijević, M, Colić, M, Popović, P, Jandrić, Dušan, "Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline" in Turkish Journal of Medical Sciences, 33, no. 3 (2001):2137-2138,
https://doi.org/10.1016/S0041-1345(01)01975-3 . .

TY  - JOUR
AU  - Arsenović-Ranin, Nevena
AU  - Vucević, D
AU  - Okada, N
AU  - Dimitrijević, M
AU  - Colić, M
PY  - 2000
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/244
AB  - A murine monoclonal antibody (mAb), 3F10, was produced by fusion of spleen cells obtained from mice immunized with a rat cortical thymic epithelial cell line (R-TNC.1) stimulated with interferon-gamma and P3X myeloma cells. 3F10 recognized an antigen expressed both on thymocytes and non-lymphoid cells in the thymus. Flow cytometry showed that 3F10 stained more than 98% thymocytes and 90% R-TNC.1 cells. Immunoprecipitation and Western blot studies demonstrated that 3F10 reacted with molecules of 55000 and 65000 MW from both thymocyte and R-TNC.1 cell lysates. 3F10 recognized the same antigen on Chinese hamster ovary cells transfected with rat Crry as did 5I2 mAb, confirming the specificity of 3F10 mAb for the rat homologue of mouse Crry/p65, a membrane-bound complement regulatory protein. 3F10 mAb induced homotypic aggregation of thymocytes and exhibited an additive effect on the aggregation evoked by phorbol myristate acetate. The aggregation was dependent on active cell metabolism, intact cytoskeleton, divalent cations and activation of protein phosphatases 1 and 2A (as assessed by use of okadaic acid). In contrast, H-7, HA1004 and genistein partially inhibited, whereas staurosporine potentiated the aggregation of thymocytes triggered by 3F10. 3F10 mAb also stimulated binding of thymocytes to the R-TNC.1 line. Both homotypic and heterotypic adhesive interactions are mediated by leucocyte function-associated antigen-1 (LFA-1). In addition, 3F10 stimulated proliferation of thymocytes induced by suboptimal concentrations of concanavalin A. These data suggest that rat Crry/p65 might be involved in the regulation of both cell adhesion and activation of thymocytes. This is a novel, non-complement-dependent function of Crry/p65.
PB  - Blackwell Science Ltd, Oxford
T2  - Immunology
T1  - A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes
VL  - 100
IS  - 3
SP  - 334
EP  - 344
DO  - 10.1046/j.1365-2567.2000.00043.x
ER  - 

@article{
author = "Arsenović-Ranin, Nevena and Vucević, D and Okada, N and Dimitrijević, M and Colić, M",
year = "2000",
abstract = "A murine monoclonal antibody (mAb), 3F10, was produced by fusion of spleen cells obtained from mice immunized with a rat cortical thymic epithelial cell line (R-TNC.1) stimulated with interferon-gamma and P3X myeloma cells. 3F10 recognized an antigen expressed both on thymocytes and non-lymphoid cells in the thymus. Flow cytometry showed that 3F10 stained more than 98% thymocytes and 90% R-TNC.1 cells. Immunoprecipitation and Western blot studies demonstrated that 3F10 reacted with molecules of 55000 and 65000 MW from both thymocyte and R-TNC.1 cell lysates. 3F10 recognized the same antigen on Chinese hamster ovary cells transfected with rat Crry as did 5I2 mAb, confirming the specificity of 3F10 mAb for the rat homologue of mouse Crry/p65, a membrane-bound complement regulatory protein. 3F10 mAb induced homotypic aggregation of thymocytes and exhibited an additive effect on the aggregation evoked by phorbol myristate acetate. The aggregation was dependent on active cell metabolism, intact cytoskeleton, divalent cations and activation of protein phosphatases 1 and 2A (as assessed by use of okadaic acid). In contrast, H-7, HA1004 and genistein partially inhibited, whereas staurosporine potentiated the aggregation of thymocytes triggered by 3F10. 3F10 mAb also stimulated binding of thymocytes to the R-TNC.1 line. Both homotypic and heterotypic adhesive interactions are mediated by leucocyte function-associated antigen-1 (LFA-1). In addition, 3F10 stimulated proliferation of thymocytes induced by suboptimal concentrations of concanavalin A. These data suggest that rat Crry/p65 might be involved in the regulation of both cell adhesion and activation of thymocytes. This is a novel, non-complement-dependent function of Crry/p65.",
publisher = "Blackwell Science Ltd, Oxford",
journal = "Immunology",
title = "A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes",
volume = "100",
number = "3",
pages = "334-344",
doi = "10.1046/j.1365-2567.2000.00043.x"
}

Arsenović-Ranin, N., Vucević, D., Okada, N., Dimitrijević, M.,& Colić, M.. (2000). A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes. in Immunology
Blackwell Science Ltd, Oxford., 100(3), 334-344.
https://doi.org/10.1046/j.1365-2567.2000.00043.x

Arsenović-Ranin N, Vucević D, Okada N, Dimitrijević M, Colić M. A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes. in Immunology. 2000;100(3):334-344.
doi:10.1046/j.1365-2567.2000.00043.x .

Arsenović-Ranin, Nevena, Vucević, D, Okada, N, Dimitrijević, M, Colić, M, "A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes" in Immunology, 100, no. 3 (2000):334-344,
https://doi.org/10.1046/j.1365-2567.2000.00043.x . .

TY  - JOUR
AU  - Dimitrijević, Miroslava
AU  - Milenković, Marina
AU  - Milosavljević, P
AU  - Stojić-Vukanić, Zorica
AU  - Colić, M
AU  - Bartlett, R
PY  - 1998
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/186
AB  - The protective and therapeutical potential of a novel immunomodulatory agent, leflunomide, has been demonstrated in several experimental models of autoimmunity reactions leading to transplant rejection, as well as the therapy of patients with rheumatoid arthritis. in this study, the effects of leflunomide on experimentally induced autoimmune myocarditis (EAM) were investigated. Genetically susceptible DA rats were immunized with porcine cardiac myosin in complete Freund's adjuvant. The course of the disease was examined (on day 8, 16, 21 and 34) by macroscopic and microscopic scoring, heart weight/body weight ratio was determined and immunohistochemical analysis of inflammatory cell infiltrates was conducted. Eight days after disease induction, only slightly elevated expression of adhesive molecules on the interstitial and vascular endothelial cells were observed otherwise no microscopic signs of the inflammation existed. On day 16, numerous inflammatory cells infiltrated the myocardium. By day 21, the severity of myocarditis was substantially increased and was accompanied by extensive necrosis. After 34 days, decreased number of infiltrated cells was detected together with myocardial necrosis. Effects of leflunomide were evaluated by two treatment protocols. Rats immunized with cardiac myosin were injected i.p. with leflunomide's active metabolite, A 771726, at a dose of 10 mg/kg/day either during the first 6 days, or starting from day 14 and ending a: day 20 after disease induction. Efficacy of leflunomide treatment was determined on day 21 of EAM development Results demonstrated that early leflunomide treatment inhibited the inflammatory reaction, while late treatment significantly reduced EAM progression. Leflunomide may be considered a potent therapeutical tool for autoimmune myocarditis.
PB  - Bioscience Ediprint Inc, Carouge
T2  - International Journal of Immunotherapy
T1  - Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats
VL  - 14
IS  - 1
SP  - 9
EP  - 21
UR  - https://hdl.handle.net/21.15107/rcub_farfar_186
ER  - 

@article{
author = "Dimitrijević, Miroslava and Milenković, Marina and Milosavljević, P and Stojić-Vukanić, Zorica and Colić, M and Bartlett, R",
year = "1998",
abstract = "The protective and therapeutical potential of a novel immunomodulatory agent, leflunomide, has been demonstrated in several experimental models of autoimmunity reactions leading to transplant rejection, as well as the therapy of patients with rheumatoid arthritis. in this study, the effects of leflunomide on experimentally induced autoimmune myocarditis (EAM) were investigated. Genetically susceptible DA rats were immunized with porcine cardiac myosin in complete Freund's adjuvant. The course of the disease was examined (on day 8, 16, 21 and 34) by macroscopic and microscopic scoring, heart weight/body weight ratio was determined and immunohistochemical analysis of inflammatory cell infiltrates was conducted. Eight days after disease induction, only slightly elevated expression of adhesive molecules on the interstitial and vascular endothelial cells were observed otherwise no microscopic signs of the inflammation existed. On day 16, numerous inflammatory cells infiltrated the myocardium. By day 21, the severity of myocarditis was substantially increased and was accompanied by extensive necrosis. After 34 days, decreased number of infiltrated cells was detected together with myocardial necrosis. Effects of leflunomide were evaluated by two treatment protocols. Rats immunized with cardiac myosin were injected i.p. with leflunomide's active metabolite, A 771726, at a dose of 10 mg/kg/day either during the first 6 days, or starting from day 14 and ending a: day 20 after disease induction. Efficacy of leflunomide treatment was determined on day 21 of EAM development Results demonstrated that early leflunomide treatment inhibited the inflammatory reaction, while late treatment significantly reduced EAM progression. Leflunomide may be considered a potent therapeutical tool for autoimmune myocarditis.",
publisher = "Bioscience Ediprint Inc, Carouge",
journal = "International Journal of Immunotherapy",
title = "Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats",
volume = "14",
number = "1",
pages = "9-21",
url = "https://hdl.handle.net/21.15107/rcub_farfar_186"
}

Dimitrijević, M., Milenković, M., Milosavljević, P., Stojić-Vukanić, Z., Colić, M.,& Bartlett, R.. (1998). Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats. in International Journal of Immunotherapy
Bioscience Ediprint Inc, Carouge., 14(1), 9-21.
https://hdl.handle.net/21.15107/rcub_farfar_186

Dimitrijević M, Milenković M, Milosavljević P, Stojić-Vukanić Z, Colić M, Bartlett R. Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats. in International Journal of Immunotherapy. 1998;14(1):9-21.
https://hdl.handle.net/21.15107/rcub_farfar_186 .

Dimitrijević, Miroslava, Milenković, Marina, Milosavljević, P, Stojić-Vukanić, Zorica, Colić, M, Bartlett, R, "Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats" in International Journal of Immunotherapy, 14, no. 1 (1998):9-21,
https://hdl.handle.net/21.15107/rcub_farfar_186 .